arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Mirum Pharmaceuticals, Inc.

MIRM

$94.10 ▼ -11.62 (-10.99%) at close

9 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Mirum Pharmaceuticals, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.7B

Dividend Yield —

Revenue Growth 54.7% ↘

Op. Margin -4.2% ↗

ROIC -7.7% ↗

FCF / Share $1.09 ↗

Trailing P/E —

Price / Book 15.5x

FCF Yield 1.2%

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$521.31M

↑ +54.7% —

Net Income Profit after all expenses

$-23.36M

↑ +73.4% —

Operating Margin Operating profit as % of sales

-4.2%

↑ +83.7% 21th

FCF / Share Free cash flow per share

$1.09

↑ +456.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↑

Financial Health ↑

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 May 2, 2018 10-K ↗
Revenue Growth YoY (%)	54.7% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+584%)	80.8% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+909%)	141.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1673%)	302.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3683%)	—	—	—	—	—
EPS Growth YoY (%)	74.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	53.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	0.2% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	-44.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	73.4% Excellent ↑ Excellent Improving Year-over-year change in net income	46.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-20.5% Weak ↑ Weak Improving Year-over-year change in net income	-61.5% Weak ↓ Weak Declining Year-over-year change in net income	18.7% Good Good Year-over-year change in net income	-96.5% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	456.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	N/M	51.2% Excellent Excellent Year-over-year change in free cash flow	18.7% Good Good Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	89.1% Excellent Excellent Compound annual revenue growth over 3 years	160.1% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 May 2, 2018 10-K ↗
Operating Margin (%) (%)	-4.2% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-128%)	-26.0% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-273%)	-58.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-490%)	-170.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1235%)	—	—	—	—	—
Effective Tax Rate (%) (%)	-9.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	4.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	-4.5% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-137%)	-26.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-318%)	-87.7% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-831%)	-176.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1567%)	-438.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3757%)	—	—	—	—
FCF Margin (%) (%)	10.5% Fair ↑ Fair Improving Free cash flow as a percentage of revenue Optimal: > 10%	2.8% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-38.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-156.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	-2.35x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.11x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.43x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.58x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 May 2, 2018 10-K ↗
Return on Invested Capital (%)	-7.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-39.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-44.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-88.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-144.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-60.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-42.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-2.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-58.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-43.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-37.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-7.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-149%)	-39.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-360%)	-65.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-538%)	-95.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-737%)	-69.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-566%)	-60.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-500%)	-40.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-369%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 May 2, 2018 10-K ↗
Interest Coverage (x)	-1.75x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-6.93x Weak Weak Operating income divided by interest expense Optimal: > 5x	-16.01x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—
Net Debt (USD)	$-296.68M	$-222.50M	$-286.33M	$-28.00M	$-31.34M	$-142.09M	$-11.97M	$-51.96M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 May 2, 2018 10-K ↗
Revenue per Share (USD)	$10.39	$7.09	$4.56	$2.28	$0.63	—	—	—	—
Basic EPS, GAAP (USD)	$-0.47	$-1.85	$-4.00	$-4.01	$-2.77	—	—	—	—
Free Cash Flow per Share (USD)	$1.09	$0.20	$-1.74	$-3.56	$-4.38	—	—	—	—
Book Value per Share (USD)	$6.06	$4.67	$5.32	$3.84	$3.93	$5.78	$5.77	$-27.19	—
Tangible Book Value per Share (USD)	$1.04	$-0.50	$-0.09	$2.25	$3.32	$5.78	$5.77	$-27.19	—
Basic Weighted Avg Shares (shares)	50.20M	47.52M	40.89M	33.84M	30.32M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 May 2, 2018 10-K ↗
Working Capital (USD)	$343.88M	$266.24M	$300.48M	$125.50M	$124.00M	$217.89M	$106.29M	$49.53M	—
Total Equity (USD)	$314.69M	$225.64M	$248.67M	$142.04M	$120.21M	$172.09M	$130.35M	$-17.31M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 May 2, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$521.31M	$336.89M	$186.37M	$77.06M	$19.14M	$0.00	—	—	—
Depreciation Expense (USD)	$24.24M	$23.63M	$10.83M	$3.24M	$595.00K	$305.00K	$139.00K	—	—
Net Income, GAAP (USD)	$-23.36M	$-87.94M	$-163.41M	$-135.66M	$-83.99M	$-103.27M	$-52.55M	—	—
Operating Cash Flow (USD)	$55.83M	$10.32M	$-70.94M	$-120.14M	$-132.76M	$-89.08M	$-39.36M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters

Mirum Pharmaceuticals, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MIRM with peers